StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Madrigal Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was -25.1%. For fiscal 2025 it was -31.3%, against -276.4% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-31.3%+245.1
FY2024Dec 31, 2024-276.4%+41180.1
FY2012Dec 31, 2012-41456.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-15.5%+6.7
Q1 FY2026Mar 31, 2026-29.8%+28.0
Q4 FY2025Dec 31, 2025-18.6%+46.3
Q3 FY2025Sep 30, 2025-39.7%+147.4
Q2 FY2025Jun 30, 2025-22.2%+1088.2
Q1 FY2025Mar 31, 2025-57.8%–
Q4 FY2024Dec 31, 2024-64.8%–
Q3 FY2024Sep 30, 2024-187.1%–
Q2 FY2024Jun 30, 2024-1110.4%–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?